• SEC Filings

On November 9, 2017, Helius Medical Technologies, Inc. (the “Company”) hosted a live webcast to report on data from the Company’s completed registrational clinical trial of the PoNS™ device for the treatment of chronic balance deficits due to mild to moderate traumatic brain injury and a recently completed long term treatment study conducted at the University of Wisconsin-Madison (the “Data”).A copy of the slides presented during the webcast is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.A transcript of the webcast is being furnished as Exhibit 99.2 to this Current Report on Form 8-K.On November 9, 2017, the Company issued a press release announcing the Data.The full text of the Company’s press release is furnished as Exhibit 99.3 to this Current Report on Form 8-K.

The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibits 99.1, 99.2 and 99.3) is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific references in such a filing.

Item 9.01.Financial Statements and Exhibits.

(d)Exhibits

HELIUS MEDICAL TECHNOLOGIES, INC. Exhibit
EX-99.1 2 hsdt-ex991_6.htm EX-99.1 hsdt-ex991_6.pptx.htm A Revolution in Mind November 9,…
To view the full exhibit click here

About HELIUS MEDICAL TECHNOLOGIES, INC. (OTCMKTS:HSDT)

Helius Medical Technologies, Inc. is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company is engaged in the development of its product, the portable neuromodulation stimulator (PoNS) device. The device, when used in combination with physiotherapy, is designed to enhance the brain’s ability to compensate for damage due to trauma or disease. The Company’s PoNS device is designed to induce cranial nerve non-invasive neuromodulation through an increase in stimulation of the facial and trigeminal nerves, which innervate the tongue. The PoNS device is developed to deliver to the tongue a non-invasive neurostimulation, in a form that induces neuromodulation. The PoNS device is an electrical pulse generator that delivers controlled electrical stimulation to the tongue.